Previous 10 | Next 10 |
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Exe...
CytRx (CYTR): Q1 Net loss of $1.3M.Cash on hand of approximately $9.3 million, which management believes is sufficient to fund ongoing operations for the foreseeable future.Press Release For further details see: CytRx reports Q1 results
Continues Focusing on Near-Term Revenue Opportunities Linked to Orphazyme’s Potential Regulatory Approvals for Arimoclomol in the Treatment of Niemann-Pick Disease Type C CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a spec...
CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that the ORARIALS-01 pivotal trial for ...
CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that its phase 2/3 trial evaluating ari...
CytRx (CYTR): FY GAAP EPS of -$0.19.Cash and cash equivalents of $10M10KPress Release For further details see: CytRx reports FY results
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the fourth quarter and fiscal...
The following slide deck was published by CytRx Corporation in conjunction with this event. For further details see: CytRx (CYTR) Investor Presentation - Slideshow
Orphazyme Announces the Global Brand Name for Arimoclomol – MIPLYFFA – Ahead of Prospective FDA and EMA Approvals Expanded its Early Access Program for NPC in the U.S. and Europe as Well as Expectation of European Regulatory Decision by Q4 2021 ...
Christophe Bourdon’s Deep Commercialization Background and Vast International Experience Make Him the Ideal CEO For Orphazyme CEO Relocation to Copenhagen Seen as a Positive Sign of the Commercial Potential of Arimoclomol CytRx Corporation (OTCQB: CYTR...
News, Short Squeeze, Breakout and More Instantly...
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, Octo...
The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceut...
Patent Protects the LADR Platform and Drugs Employing LADR CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has...